ClinicalTrials.gg
CompletedNCT06973291Updated May 1, 2026

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

A Phase 3 interventional study of Zasocitinib and Deucravacitinib in Plaque Psoriasis, sponsored by Takeda. Completed at 113 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Takeda · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
606
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 764 studies in Psoriasis with a site in United States — 55 open to participants now, 86 under way, 19 of them phase 3. Psoriasis · United States.

Enrollment
70th of 673
606 · median 77
Started
2025
with 24 others
Phase 3
188 of 764
6 open now
Registered
732nd of 764
by date

Among the 764 studies in Psoriasis with a site in United States, this one is the 70th largest by enrollment of the 673 interventional ones that give a count, is one of 25 that started in 2025, is one of 188 in phase 3, and was the 732nd registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

55 of the 764 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:

50 more — sign in →

All 55 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 764 studies in Psoriasis with a site in United States, or all of them as a file.
02

Study summary

The main aim of this study is to assess whether zasocitinib works better than deucravacitinib in treating participants with moderate-to-severe plaque psoriasis.

Participants will take one tablet daily of either zasocitinib or a matching placebo, along with one capsule daily of either over-encapsulated deucravacitinib or a matching placebo, for a duration of 16 weeks.

Participants will be in the study for up to 25 weeks, which includes screening period of up to 35 days, a 16-week treatment period, and a 4-week safety follow-up period.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

Keywords

  • Drug Therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has a diagnosis of chronic plaque psoriasis for >=6 months prior to the screening visit.
  2. Participant has stable plaque psoriasis, defined as no significant flare or change in morphology (as assessed by the investigator) in psoriasis, for >=6 months before screening.
  3. Participant has moderate-to-severe plaque psoriasis, as defined by a PASI score >=12 and an sPGA score >=3, at screening and Day 1.
  4. Participant has plaque psoriasis covering >=10 percent (%) of his or her total body surface area (BSA) at screening and Day 1.
  5. Participant must be a candidate for phototherapy or systemic therapy.

Exclusion criteria

Exclusion Criteria:

- Target Disease-Related Exclusions:

  1. Participant has evidence of nonplaque psoriasis (erythrodermic, pustular, predominantly guttate psoriasis, predominantly inverse, or drug-induced psoriasis). If a participant meets criteria for inclusion based on typical plaque psoriasis presentation, a limited amount of inverse psoriasis is not exclusionary.
  2. Participant requires systemic treatment, other than nonsteroidal anti-inflammatory drugs, during the trial period for an immune related disease (for example, inflammatory bowel disease).
  3. Participant has a history of excessive sun exposure, has used tanning booths within 4 weeks prior to Day 1, or is not willing to minimize natural and artificial sunlight exposure during the trial period. Use of sunscreen products and protective apparel is recommended when sun exposure cannot be avoided.
  4. Participant has concomitant comorbid skin condition that, in the opinion of the investigator, would interfere with the trial assessments.

    Recent/Concurrent Infectious Disease Exclusions:

  5. Tuberculosis (TB):

    1. Participant has history of active TB infection, regardless of treatment status.
    2. Participant has signs or symptoms of active TB (including, but not limited to, chronic fever, chronic productive cough, night sweats, or weight loss) as judged by the investigator.
    3. Participant has evidence of latent TB infection (LTBI) as evidenced by a positive QuantiFERON-TB Gold (QFT) result OR 2 indeterminate QFT results, and participant does not have documentation of appropriate LTBI prophylaxis or is not able or not willing to initiate appropriate LTBI prophylaxis.
    4. Participant has had any imaging trial during or 6 months prior to screening, including x-ray, chest computed tomography, Magnetic Resonance Imaging (MRI), or other chest imaging suggesting evidence of current active or a history of active TB. X-ray is required for all participants regardless of QFT results unless the participant has had normal chest imaging in the 6 months prior to screening.
  6. Herpes infections:

    1. Participant has active herpes virus infection, including herpes zoster or herpes simplex 1 and 2 (demonstrated on physical examination and/or medical history) at screening or Day 1.
    2. Participant has history of serious herpetic infection that includes any episode of disseminated disease, multidermatomal herpes zoster, herpes encephalitis, ophthalmic herpes, or recurrent herpes zoster (defined as 2 episodes within 2 years).
  7. Nonherpetic viral diseases:

    1. Participant has presence of Virus (HCV) antibody and a positive confirmatory test result for HCV ribonucleic Acid (RNA) (nucleic acid test or Polymerase Chain Reaction [PCR]).
    2. Participant has presence of positive Surface Antigen (HBsAg+), or indeterminate HBsAg, presence of HBV deoxyribonucleic Acid (DNA) (regardless of serology), or positive anti-hepatitis B core antibody without concurrent positive hepatitis B surface antibody (Hepatitis B Core Antibody [HBcAb] positive and Hepatitis B Surface Antibody [HBsAb] negative).
    3. Participant has positive results for (HIV) by serology, regardless of viral load.
  8. Other infectious diseases:

    1. Participant has a history of active infection or febrile illness within 7 days prior to Day 1, as assessed by the investigator.
    2. Participant has history of symptoms suggestive of systemic or invasive infection within 30 days prior to Day 1.
    3. Participant has history of bacterial, viral, or fungal infection that required hospitalization or treatment with intravenous antimicrobial therapy within 8 weeks prior to Day 1 or oral antimicrobial therapy within 30 days prior to Day 1.
    4. Participant has a history of chronic or recurrent bacterial disease, including but not limited to chronic pyelonephritis or cystitis, chronic bronchitis/pneumonitis, osteomyelitis, or chronic skin ulcerations/infections or fungal infections (except superficial onychomycosis).
    5. Participant has a history of an infected joint prosthesis, unless that prosthesis has been removed or replaced at least 60 days prior to Day 1.
    6. Participant has a history of opportunistic infections (for example, Pneumocystis jirovecii pneumonia, histoplasmosis, coccidiomycosis).
    7. Participant had a bacterial infection within 60 days prior to Day 1 for which he or she did not receive treatment.

      • Noninfectious Disorders Exclusions:
  9. Participant has any medical condition, evidence of an unstable clinical condition (for example, cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, or immunologic), or vital signs/physical/laboratory/ (ECG) abnormality that would, in the opinion of the investigator, put the participant at undue risk or interfere with interpretation of trial results. These include but are not limited to:

    1. Participant has a history of known or suspected condition/illness that is consistent with compromised immunity, including but not limited to any identified congenital or acquired immunodeficiency, splenectomy.
    2. Participant had a major surgery within 60 days prior to Day 1 or has a major surgery planned during the trial.
    3. Participant has unstable, poorly controlled, or severe hypertension at screening, confirmed by 2 repeat assessments.
    4. Participant has a history of Class III or IV congestive heart failure as defined by criteria.
    5. Participant has a history of cancer or lymphoproliferative disease, with the exception of successfully treated nonmetastatic cutaneous squamous cell or basal cell carcinoma and/or localized carcinoma in situ of the cervix.
    6. For participants with asthma, , or other pulmonary illnesses, participant has been hospitalized in the past 3 months, has ever required intubation for treatment, currently requires oral , or has required more than 1 course of oral corticosteroids within 6 months prior to Day 1.
    7. Participant has any of the following cardiovascular disease history:

      • A new diagnosis of atrial fibrillation or an episode of atrial fibrillation with rapid ventricular response or other dysrhythmia, nonacute cardiac hospitalization (for example, pacemaker implantation), pulmonary embolism, or deep venous thrombosis within the past 6 months prior to screening.
      • Any history of cerebrovascular event, myocardial infarction, coronary stenting, or aorto-coronary bypass surgery. If, however, the investigator determines there are no suitable treatment alternatives available for the participant and it has been at least 6 months since the occurrence of any such event, the participant may enroll.
    8. Participant has ECG abnormalities that are considered clinically significant and would pose an unacceptable risk to the participant if he or she participated in the trial, in the opinion of the investigator.
    9. Participant has significant/uncontrolled psychiatric illness, in the opinion of the investigator.
    10. Participant has a history of clinically significant drug or alcohol abuse within 12 months prior to Day 1.

      • Prohibited Psoriasis Treatments Exclusions:

    For the below prohibited psoriasis treatments, the prior to Day 1 is within the time frame indicated or 5 half-lives, whichever is longer, regardless of whether they are prescribed for psoriasis or another condition:

  10. Participant has received any of the following biologics or biosimilar versions within the time frame indicated:

    1. Antibodies to interleukin (IL)-12/-23, IL-17, or IL-23 (for example, ustekinumab, secukinumab, tildrakizumab, ixekizumab, or guselkumab) within 6 months prior to Day 1.
    2. Tumor Necrosis Factor (TNF) inhibitor(s) (for example, etanercept, adalimumab, infliximab, or certolizumab) within 2 months prior to Day 1.
    3. Agents that modulate integrin pathways to impact lymphocyte trafficking (for example, natalizumab) or agents that modulate B cells or T cells (for example, alemtuzumab, abatacept, or visilizumab) within 3 months prior to Day 1.
    4. Rituximab or other immune cell-depleting therapy within 6 months prior to Day 1.
  11. Participant has used medicated shampoo and/or body wash, including formulations containing but not limited to salicylic acid, corticosteroids, coal tar, vitamin D3 analogues, or other compounds used for the management of psoriasis within 2 weeks prior to Day 1.
  12. Participant has used any topical medication that could affect psoriasis presentation (including but not limited to corticosteroids, salicylic acid, urea, alpha- or beta-hydroxy acids, anthralin, retinoids, vitamin D analogues [such as calcipotriol], methoxsalen, trimethylpsoralen, calcineurin inhibitors [for example, tacrolimus], tapinarof, roflumilast, Janus kinase (JAK) inhibitors, or tar) within 2 weeks prior to Day 1.
  13. Participant has used any systemic nonbiologic treatment that could affect psoriasis presentation (including oral, intravenous, intramuscular, intra-articular, intrathecal, or intralesional corticosteroids; oral retinoids; /immunomodulating medication; methotrexate; azathioprine; 6-thioguanidine; mercaptopurine; mycophenolate mofetil; hydroxyurea; cyclosporine; 1,25-dihydroxyvitamin D3 analogues; psoralens; sulfasalazine; fumaric acid derivatives; JAK inhibitors; apremilast) within 4 weeks prior to Day 1, or 5 half-lives, whichever is longer. Note: Intranasal corticosteroids, inhaled corticosteroids, and eye and ear drops containing corticosteroids are permitted.
  14. Participant has used leflunomide within 6 months prior to Day 1.
  15. Participant has received phototherapy (including Ultraviolet B [UV B], Psoralen plus Ultraviolet A [PUVA], tanning beds, therapeutic sunbathing) or excimer laser within 4 weeks prior to Day 1.
  16. Participant has used botanical preparations (for example, herbal supplements or traditional medicines, including traditional Chinese medicines derived from plants, minerals, or animals) intended to treat psoriasis or other immunological diseases within 4 weeks prior to Day 1.
  17. Participant is currently being treated with oral antihistamines for any reason, with the exception of oral antihistamines that are administered at a stable dose for at least 4 weeks prior to Day 1. Note: Additional treatment with oral antihistamines may be permitted after discussion with the medical monitor.
  18. Participant has any previous exposure to zasocitinib (also known as TAK-279 or NDI 034858) or other Tyrosine Kinase 2 (TYK2) inhibitors (including deucravacitinib), or participated in any trial that included a TYK2 inhibitor (for example, deucravacitinib, VTX958, GLPG3667, et cetera), unless participant has documentation of posttrial unblinding that confirms the participant did not receive a TYK2 inhibitor.

    - Other Prohibited Concomitant Medications Exclusions: For the below prohibited concomitant medications, where applicable, the washout period prior to Day 1 is within the time frame indicated or 5 half-lives, whichever is longer.

  19. Participant has received lithium, antimalarials, or intramuscular gold therapy within 4 weeks prior to Day 1.
  20. Participant is currently being treated with strong or moderate Cytochrome P450 3A4 () inhibitors (such as itraconazole) or strong or moderate CYP3A4 inducers (such as rifampin, carbamazepine, or phenytoin), or has received strong or moderate CYP3A4 inhibitors or strong or moderate CYP3A4 inducers within 4 weeks or 5 half-lives of the inducer or inhibitor, whichever is longer, prior to Day 1, or is anticipated to require treatment with strong or moderate CYP3A4 inducers or inhibitors during the trial period.

    Note: This includes consumption of food or beverages containing grapefruit and/or Seville oranges within 1 week of Day 1. Participants must be counseled to avoid food or beverages containing grapefruit and/or Seville oranges for the duration of the trial.

  21. Participant has received any within 60 days prior to Day 1 or plans to receive a live-attenuated vaccine during the trial and up to 4 weeks after the last trial intervention administration.

    Note: Non-live-attenuated vaccines or boosters for Coronavirus Disease 2019 (COVID-19) or influenza are permitted during the trial.

  22. Participant received an antibody or biologic therapy within 6 months prior to Day 1.
  23. Participant received an investigational oral therapy within 3 months prior to Day 1.
  24. Participant is currently receiving a nonbiological trial intervention or device or has received one within 4 weeks prior to Day 1.
  25. Participant is currently enrolled in a clinical trial or anticipates enrollment in a clinical trial during the course of the trial.

    - Laboratory/Physical Exclusions:

  26. Participant has any of the following laboratory values at the screening visit:

    1. (AST) or alanine aminotransferase (ALT) values greater than (˃)3* (ULN).
    2. Total (Tbili) (unconjugated and/or conjugated) ˃1.5*ULN.
    3. less than (\<) 9.0 grams per deciliter (g/dL) (\<90.0 grams per liter [g/L]).
    4. Absolute white blood cell (WBC) count \<3.0*109/liters (L) (\<3000 per cubic millimeter [/mm3]).
    5. of \<1.0*109/L (\<1000/mm3).
    6. Absolute lymphocytes count of \<0.5*109/L (\<500/mm3).
    7. count \<100*109/L (\<100,000/mm3).
    8. Thyroid-stimulating hormone outside the normal reference range AND free T4 or T3 outside the normal reference range.
    9. Estimated \<45 milliliters per minute (mL/min) based on the Cockcroft-Gault calculation.
    10. Creatine phosphokinase (CPK) > ULN. CPK may be repeated once; if repeat value is (CTCAE) Grade 1 or lower (or \<=2.5*ULN) and no higher than the initial value, participant remains eligible. Investigators should assess the participant for modulating factors, including concomitant medications or vigorous exercise, that may affect CPK levels.
  27. Participant has any other significant laboratory abnormalities that, in the opinion of the investigator, might place the participant at unacceptable risk for participation in this trial.
  28. Participant does not tolerate venipuncture or inability to be venipunctured.

    - Allergies and Adverse Drug Reactions Exclusions:

  29. Participant has history of significant drug allergy (such as anaphylaxis).
  30. Participant has a known or suspected allergy to zasocitinib or deucravacitinib or any of their components.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
606 participants (actual)

Study arms

  • Experimental
    Zasocitinib or Placebo

    Participants will receive zasocitinib or matching placebo tablet, orally, once daily (QD) up to Week 16.

    Drug: Zasocitinib · Drug: Placebo to match zasocitinib

  • Active comparator
    Deucravacitinib or Placebo

    Participants will receive deucravacitinib 6 mg or matching placebo capsule, orally, QD up to Week 16.

    Drug: Deucravacitinib · Drug: Placebo to match deucravacitinib

Interventions

  • Zasocitinib tablets.

    Also known as: TAK-279, NDI-034858

  • Deucravacitinib capsules.

  • DrugPlacebo to match zasocitinib

    Zasocitinib matching placebo tablets.

  • DrugPlacebo to match deucravacitinib

    Deucravacitinib matching placebo capsules.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI)-100 at Week 16

    PASI is a measure of the average erythema, induration/infiltration, and desquamation/scaling of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72 (less than or equal to \[\<=\] 3 representing mild disease, greater than or equal to \[\>=3\] to 15 representing moderate disease, and \>=15 indicating severe disease) with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100 percentage (%) improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: At Week 16

Secondary outcomes

  1. Percentage of Participants Achieving PASI-90 at Weeks 4, 8, 12, and 16

    PASI is a measure of the average erythema, induration/infiltration, and desquamation/scaling of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72 (\<= 3 representing mild disease, \>=3 to 15 representing moderate disease, and \>=15 indicating severe disease) with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 90% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: At Weeks 4, 8, 12, and 16

  2. Percentage of Participants Achieving PASI <=2 Response at Weeks 4, 8, 12, and 16

    PASI is a measure of the average erythema, induration/infiltration, and desquamation/scaling (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72 (\<= 3 representing mild disease, \>=3 to 15 representing moderate disease, and \>=15 indicating severe disease) with higher PASI scores denoting more severe disease activity. Percentage of participants achieving PASI \<=2 at Weeks 4, 8, 12, and 16 will be reported.

    Time frame: At Weeks 4, 8, 12, and 16

  3. Percentage of Participants Achieving Static Physician's Global Assessment (sPGA) of Clear (0) at Weeks 4, 8, 12, and 16

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' will include all participants who score a 0.

    Time frame: At Weeks 4, 8, 12, and 16

  4. Percentage of Participants Achieving PASI-100 at Weeks 4, 8, and 12

    PASI is a measure of the average erythema, induration/infiltration, and desquamation/scaling of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72 (\<= 3 representing mild disease, \>=3 to 15 representing moderate disease, and \>=15 indicating severe disease) with higher PASI scores denoting more severe disease activity. Percentage of participants showing 100% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: At Weeks 4, 8, and 12

  5. Percentage of Participants Achieving PASI-75 at Weeks 4, 8, 12, and 16

    PASI is a measure of the average erythema, induration/infiltration, and desquamation/scaling of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72, with higher PASI scores denoting more severe disease activity. Percentage of participants showing at least 75% improvement in PASI score relative to baseline PASI score will be reported.

    Time frame: At Weeks 4, 8, 12, and 16

  6. Percentage of Participants Achieving sPGA of Clear (0) or Almost Clear (1) at Weeks 4, 8, 12, and 16

    The sPGA is a 5-point scale of an average assessment of all psoriatic lesions based on erythema, scaling, and induration. The average of the 3 scales, rounded to the nearest whole number, is the final sPGA score. The sPGA score ranges from 0 to 4 (0 = Clear; 1 = Almost clear; 2 = Mild; 3 = Moderate; 4 = Severe). Higher scores indicate more severe disease activity. 'Clear' and 'Almost clear' will include all participants who score a 0 or 1.

    Time frame: At Weeks 4, 8, 12, and 16

  7. Change From Baseline in PASI Score at Weeks 4, 8, 12, and 16

    PASI is a measure of the average erythema, induration/infiltration, and desquamation/scaling of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72 (\<= 3 representing mild disease, \>=3 to 15 representing moderate disease, and \>=15 indicating severe disease) with higher PASI scores denoting more severe disease activity. Change from baseline will be calculated as post-baseline value minus baseline value.

    Time frame: Baseline, Weeks 4, 8, 12, and 16

  8. Percent Change From Baseline in PASI score at Weeks 4, 8, 12, and 16

    PASI is a measure of the average erythema, induration/infiltration, and desquamation/scaling of psoriatic skin lesions (each graded on a 0 to 4 scale; 0 = none to 4 = very severe), weighted by the area of involvement (head, upper extremities, trunk, and lower extremities). The PASI produces a numeric score that can range from 0 to 72 (\<= 3 representing mild disease, \>=3 to 15 representing moderate disease, and \>=15 indicating severe disease) with higher PASI scores denoting more severe disease activity. Percent change from baseline will be calculated as post-baseline value minus baseline value multiplied by 100.

    Time frame: Baseline, Weeks 4, 8, 12, and 16

07

Study locations

113 sites
  • Johnson Dermatology
    Fort Smith, Arkansas 72916-6103, United States
  • Burke Pharmaceutical Research
    Hot Springs, Arkansas 71913-6475, United States
  • Zenith Research, Inc.
    Beverly Hills, California 90212, United States
  • First OC Dermatology Research Inc.
    Fountain Valley, California 92708, United States
  • UNISON Clinical Trials (Shahram Jacobs md inc.)
    Sherman Oaks, California 91403, United States
  • Central Connecticut Dermatology, PLLC
    Cromwell, Connecticut 06416, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06511, United States
  • Direct Helpers Research Center
    Hialeah, Florida 33012, United States
  • San Marcus Research Clinic Inc
    Miami Lakes, Florida 33014, United States
  • Advanced Clinical Research Institute
    Tampa, Florida 33607-6429, United States
  • Arlington Dermatology
    Rolling Meadows, Illinois 60008-3811, United States
  • Endeavor Health Clinical Trials
    Skokie, Illinois 60077, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • Lawrence J Green, MD LLC
    Rockville, Maryland 20850, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • JDR Dermatology Research, LLC
    Las Vegas, Nevada 89145, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Markowitz Medical PLLC dba OptiSkin Medical
    New York, New York 10128, United States
  • University of North Carolina at Chapel Hill
    Chapel Hill, North Carolina 27516, United States
  • Bexley Dermatology Research - Probity - PPDS
    Bexley, Ohio 43209, United States
  • Apex Clinical Research Center, LLC - Canton
    Canton, Ohio 44718, United States
  • Apex Clinical Research Center, LLC - Mayfield Heights
    Mayfield Heights, Ohio 44124-4005, United States
  • UPMC Department of Dermatology
    Pittsburgh, Pennsylvania 15213-3403, United States
  • Goodlettsville Dermatology Research
    Goodlettsville, Tennessee 37072, United States
  • Arlington Research Center
    Arlington, Texas 76011-3800, United States
  • Bellaire Dermatology Associates
    Bellaire, Texas 77401-3505, United States
  • The University of Texas Health Science Center at Houston (UTHSC-H)
    Bellaire, Texas 77401, United States
  • Reveal Research Institute
    Dallas, Texas 75235, United States
  • San Antonio
    San Antonio, Texas 78213-2250, United States
  • Texas Dermatology and Laser Specialists-San Antonio
    San Antonio, Texas 78218-3128, United States
  • Houston Center for Clinical Research, LLC
    Sugar Land, Texas 77479-1001, United States
  • Medical Centre Femiclinic EOOD
    Sofia, Dianabad District 1113, Bulgaria
  • Medical Center Unimed EOOD-Sevlievo
    Sevlievo, Gabrovo 5400, Bulgaria
  • Medical Center Asklepii OOD
    Dupnitsa, Kyustendil 2600, Bulgaria
  • Diagnostic and Consulting Center Aleksandrovska EOOD
    Sofia, Sofia-Grad 1431, Bulgaria
  • Medical Center Hera EOOD-Sofia
    Sofia, Sofia-Grad 1510, Bulgaria
  • Diagnostic Consultative Center XXVIII - Sofia - EOOD
    Sofia, Sofia-Grad 1592, Bulgaria
  • Military Medical Academy Multiprofile Hospital for Active Treatment - Sofia
    Sofia, Sofia-Grad 1606, Bulgaria
  • Multiprofile Hospital For Active Treatment Dr Tota Venkova
    Gabrovo, 5300, Bulgaria
  • Diagnostic Consultative Center Sveti Georgi EOOD
    Haskovo, 6300, Bulgaria
  • Medical Center Medconsult Pleven - Lovech Branch
    Lovech, 5500, Bulgaria
  • Beacon Dermatology - Probity
    Calgary, Alberta T3E 0B2, Canada
  • VIDA Dermatology - Probity
    Edmonton, Alberta T6H 4J8, Canada
  • Enverus Medical Research - Probity
    Surrey, British Columbia V3V 0C6, Canada
  • Dr Chih-Ho Hong Medical Inc
    Surrey, British Columbia V3V 6A7, Canada
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Brunswick Dermatology Centre - Probity
    Fredericton, New Brunswick E3B 1G9, Canada
  • Lima's Excellence In Allergy And Dermatology Research (Leader) Inc. - Probity
    Hamilton, Ontario L8L 3C3, Canada
  • Dermatrials Research
    Hamilton, Ontario L8N 1Y2, Canada
  • Lynderm Research Inc - Probity
    Markham, Ontario L3P 1X3, Canada
  • North Bay Dermatology Center - Probity
    North Bay, Ontario P1B 3Z7, Canada
  • The Centre for Clinical Trials Inc.
    Oakville, Ontario L6J 7W5, Canada
  • Skin Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • The Centre For Dermatology
    Richmond Hill, Ontario L4B 1A5, Canada
  • Alliance Clinical Trials
    Waterloo, Ontario N2J 1C4, Canada
  • XLR8 Medical Research
    Windsor, Ontario N8T1E6, Canada
  • Siena Medical Research Corporation
    Montreal, Quebec H3Z 2S6, Canada
  • Skinsense Medical Research
    Saskatoon, Saskatchewan S7K 2C1, Canada
  • Centre de Recherche Dermatologique du Quebec Metropolitain
    Québec, G1V 4X7, Canada
  • Nemocnice AGEL Novy Jicin a.s
    Nový Jičín, Moravian-Silesian Region 741 01, Czechia
  • CCR Ostrava s.r.o.
    Ostrava, Moravian-Silesian Region 702 00, Czechia
  • Dermskin s.r.o
    Olomouc, Olomouc Region 779 00, Czechia
  • Pratia Brno s.r.o. - PRATIA - PPDS
    Brno, South Moravian 602 00, Czechia
  • Pratia Pardubice
    Pardubice, 53002, Czechia
  • CLINTRIAL s.r.o.
    Prague, 100 00, Czechia
  • Prof. MUDr. Petr Arenberger, DrSc. - CRC - PPDS
    Prague, 110 00, Czechia
  • Praglandia s.r.o.
    Prague, 150 00, Czechia
  • Office of Mireille Ruer-Mulard, MD
    Martigues, Paca 13500, France
  • Centre Hospitalier Le Mans
    Le Mans, Sarthe 72037, France
  • Hopital Charles Nicolle-1 Rue de Germont
    Rouen, 76031, France
  • Centre Hospitalier Universitaire de Saint Etienne
    Saint-Etienne, 42270, France
  • Nagoya City University Hospital
    Nagoya, Aichi-ken 467-8602, Japan
  • Fukuoka University Hospital
    Fukuoka, Fukuoka 814-0180, Japan
  • Hino Dermatology Clinic
    Fukutsu-shi, Fukuoka 811-3217, Japan
  • JR Sapporo Hospital
    Sapporo, Hokkaido 060-0033, Japan
  • Investigational Product department
    Sapporo, Hokkaido 060-0063, Japan
  • Nippon Life Hospital
    Osaka, Osaka 550-0006, Japan
  • Investigational Product department Dermatology and Ophthalmology Kume Clinic
    Sakai-shi, Osaka 593-8324, Japan
  • Seikoukai Omi Medical Center
    Kusatsu-shi, Shiga 525-8585, Japan
  • Jichi Medical University Hospital
    Shimotsuke-shi, Tochigi 329-0498, Japan
  • St. Luke's International Hospital
    Chuo-ku, Tokyo 104-8560, Japan
  • Tokyo Medical University Hospital
    Shinjuku-Ku, Tokyo 160-0023, Japan
  • Medical Corporation Jitai-kai Tachikawa Dermatology Clinic
    Tachikawa-shi, Tokyo 190-0023, Japan
  • JCHO Tokyo Yamate Medical Center
    Shinjuku-ku, Tokyo-to 169-0073, Japan
  • Shirasaki Dermatology Clinic
    Takaoka-shi, Toyama 933-0871, Japan
  • Ohyama Dermatology Clinic
    Kumamoto, 861-4101, Japan
  • Semigallia
    Kuldīga, LV-3301, Latvia
  • Health Center 4, Center of Diagnostics
    Riga, 1003, Latvia
  • Health Center 4, Clinic of Dermatology
    Riga, 1013, Latvia
  • Riga 1st Hospital
    Riga, LV-1001, Latvia
  • Aesthetic dermatology clinic of prof. J. Kisis
    Riga, LV-1003, Latvia
  • Veseliba un estetika Ltd.
    Riga, LV-1009, Latvia
  • Outpatient Clinic Adoria
    Riga, LV-1011, Latvia
  • DermoDent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski, s.c.
    Osielsko, Kuyavian-Pomeranian Voivodeship 86-031, Poland
  • Krakowskie Centrum Medyczne Sp. z o.o.
    Krakow, Lesser Poland Voivodeship 31-501, Poland
  • Dermedic Jacek Zdybski
    Ostrowiec Swietokrzyski, Lower Silesian Voivodeship 27-400, Poland
  • Cityclinic Przychodnia lekarsko psychologiczna Matusiak sp.p
    Wroclaw, Lower Silesian Voivodeship 50-566, Poland
  • Centrum Columbus
    Wroclaw, Lower Silesian Voivodeship 51-503, Poland
  • Luxderm Specjalistyczny Gabinet Dermatologiczny Dorota Krasowska
    Lublin, Lublin Voivodeship 20-573, Poland
  • MICS Centrum Medyczne Warszawa
    Warsaw, Masovian Voivodeship 00-874, Poland

Showing the first 100 of 113 sites across 8 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2025 to primary completion in Apr 2026, 9 months.

Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 9 months is below that.

Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2025
First posted
May 15, 2025
StartActual
Jul 9, 2025
Primary completionActual
Apr 22, 2026
CompletionActual
Apr 22, 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06973291
Lead sponsor
Takeda
Responsible party
Sponsor
First posted
May 15, 2025
Start date
Jul 9, 2025
Primary completion
Apr 22, 2026
Completion
Apr 22, 2026
Last update
May 1, 2026

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zasocitinib

Start the discussion